New Treatments for a Common Pediatric Brain Tumor

Study helps explain launch switch for the most common malignant pediatric brain tumor.

New study details the mechanisms underlying development of a common pediatric brain tumor called medulloblastoma. These findings could lead to new treatments for the condition.

Medulloblastoma of the Sonic Hedgehog subtype can occur at any age, but this type of

Medulloblastoma Targeting By Repurposing Anti-Depressant Medication
A novel molecular pathway that causes an aggressive form of medulloblastoma has been reported by an international research team in Nature Medicine.

‘Focusing on Gpr161 might be a new strategy to inhibit progression of tumors that develop resistance to drugs targeting the upstream Sonic Hedgehog pathway.’

Medulloblastomas originate in the cerebellum, an area at the skull's base that regulates motor control, posture, and balance. The Sonic Hedgehog subtype of medulloblastoma occurs when too many of a particular brain cell type -- granule cells -- are made. Granule cells make up most of the cerebellum and constitute as much as 80 percent of all brain neurons. During normal development, many granule cells are made when other nearby cells release the protein Sonic Hedgehog. However, some granule cells are made in the cerebellum even before Sonic Hedgehog is released, which led the researchers to investigate other factors that regulate early granule cell production.

"We modeled the Sonic Hedgehog medulloblastoma in mice by deleting a gene for a G protein-coupled receptor called Gpr161 that was not known to be involved in this tumor," said first author Dr. Issei Shimada, Assistant Instructor in Cell Biology. "Interestingly, we found that in the absence of Gpr161, which actively represses the downstream pathway, the granule cells proliferate even before Sonic Hedgehog is secreted."

Dr. Mukhopadhyay added, "Repression of the downstream pathway in the absence of Sonic Hedgehog is as important as activation in its presence. Bottom line: The granule cell behaves like a car on a downhill slope with the hand brake on. Loss of the hand brake is as damaging as the accelerator being pressed too hard."

Researchers Develop New Approach to Treat Brain Cancer With Better Outcomes
Researchers at Sanford-Burnham Medical Institute (Sanford-Burnham) have developed a new experimental approach to treating a type of brain cancer called medulloblastoma.

This means that Gpr161 acts as a tumor suppressor for Sonic Hedgehog medulloblastomas by preventing too many granule cells from being made.

Medulloblastomas account for 15 to 20 percent of all pediatric brain tumors, according to the National Institutes of Health. While they are most commonly diagnosed in children between ages 3 and 8, they can be seen in all age groups. About 350 cases are diagnosed each year in the U.S.

AI can Predict Survival of Patients with Brain Tumors
Deep-learning algorithm can be used to anticipate how long the patients will survive after they were diagnosed with brain tumors.

In 2017, a survey of the National Cancer Database tracked 4,032 patients with medulloblastomas. Of these, 1,300 were age 18 or younger and received chemotherapy and radiation treatment. The median age was 8.4 years, and the group's five-year survival rate was 79 percent.

Only one drug, vismodegib, currently targets the upstream Sonic Hedgehog pathway for treating these pediatric tumors, Dr. Mukhopadhyay said. Now that this work has identified Gpr161 as a tumor suppressor, focusing on Gpr161 might be a new strategy to inhibit progression of tumors that develop resistance to drugs targeting the upstream Sonic Hedgehog pathway, he said.

HET0016 inhibitor may Help Control the Growth of Brain Tumors
HET0016, a chemical inhibitor enzyme can help limit the growth of brain tumor and metastatic breast cancer by deactivating a chemical that promotes cancer.

Source-Eurekalert